title: Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1, in vitro.
abstract: Pancreatic cancer is an aggressive disease that responds poorly to conventional photon radiotherapy. Carbon-ion (C-ion) radiation has advantages compared with conventional radiotherapy, because it enables more accurate dose distribution and more efficient tumor cell killing. To elucidate the effects of local radiotherapy on the characteristics of metastatic tumors, it is necessary to understand the nature of motility in irradiated tumor cells; this will, in turn, facilitate the development of effective strategies to counter tumor cell motility, which can be used in combination with radiotherapy. The aim of the present study was to examine the invasiveness of pancreatic cancer cells exposed to C-ion irradiation. We found that C-ion irradiation suppressed the migration of MIAPaCa-2, BxPC-3 and AsPC-1; diminished the invasiveness of MIAPaCa-2; and tended to reduce the invasion of BxPC-3 and AsPC-1. However, C-ion irradiation increased the invasiveness of PANC-1 through the activation of plasmin and urokinase-type plasiminogen activator. Administration of serine protease inhibitor (SerPI) alone failed to reduce C-ion-induced PANC-1 invasiveness, whereas the combination of SerPI and Rho-associated coiled-coil forming protein kinase (ROCK) inhibitor suppressed it. Furthermore, PANC-1 showed mesenchymal-amoeboid transition when we treated with SerPI alone. In conclusion, C-ion irradiation is effective in suppressing the invasive potential of several pancreatic tumor cell lines, but not PANC-1; this is the first study showing that C-ion irradiation induces the invasive potential of a tumor cell line. Further in vivo studies are required to examine the therapeutic effectiveness of radiotherapy combined with inhibitors of both mesenchymal and amoeboid modes of tumor cell motility.
authors.affiliation: Advanced Radiation Biology Research Program, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Fujita
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Otsuka
authors.forename: Kaori
authors.initials: K
authors.lastname: Imadome
authors.forename: Satoshi
authors.initials: S
authors.lastname: Endo
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yamada
authors.forename: Takashi
authors.initials: T
authors.lastname: Imai
mesh_terms: D002244:Carbon / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000528:radiation effects*; D006801:Humans; D007477:Ions; D020778:Matrix Metalloproteinase 2; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D010960:Plasminogen Activators / Q000378:metabolism; D057057:Serine Proteases / Q000378:metabolism; D054460:rho-Associated Kinases / Q000378:metabolism
chemical_list: D007477:Ions; D002244:Carbon; D054460:rho-Associated Kinases; D057057:Serine Proteases; D010960:Plasminogen Activators; D020778:Matrix Metalloproteinase 2